[FDA Consumer Magazine]


[FDA offers free, easy-to-read health brochures]

VOL. 31 NO. 5

JULY-AUGUST 1997


Features

Dieter's Brews Make Tea Time a Dangerous Affair
The active ingredients in dieter's teas--herbal laxatives--won't help you lose weight, and may cause cramps, diarrhea and even more severe problems.

When Summertime Gets Too Hot to Handle
Hot fun in the summertime can sometimes have serious, even lethal, consequences. But a few simple precautions can prevent heat-related illness.

A Dose of Clear Directions for Rx Drug Users
The simple--and uninformative--phrase "use as directed" will give way to detailed information in nonmedical language on all prescription drugs under a new voluntary plan FDA will monitor.

Bulking Up Fiber's Healthful Reputation
"Beans, beans, the musical fruit. The more you eat, the more you toot." Fiber--with all its many contributions to health--deserves more respect than that.

Incontinence Can Be Controlled
Urinary incontinence can devastate a person's quality of life. But myriad treatment options, including two new devices FDA approved in 1996, can bring the quality back.

On the Teen Scene: Overcoming the Deficit of Attention Disorder
Teens with attention-deficit/hyperactivity disorder need more than adults yelling at them to pay attention. Drugs and coping skills can help them succeed in school and life.


Departments

Updates
The latest information on FDA-related issues, gathered from FDA Press Releases, Talk Papers, and other sources.

Notebook
A potpourri of items of interest gathered from the Federal Register and other sources.

Investigators' Reports
Selected cases illustrating regulatory and administrative actions--such as inspections, recalls, seizures, and court proceedings--by FDA's regional and district offices across the country

Summaries of Court Actions
Cases involving seizure, criminal and injunction proceedings.

How to Subscribe   |   Back Issues   |   Publications Catalog   |   FDA Home Page


Questions concerning the editorial content of FDA Consumer should be directed to FDA's Office of Public Affairs.